OT mobile menu

Search form


Gastrointestinal Cancer Targets

What Is Your Experience With Regorafenib?

Have you seen patients on regorafenib with palmar-plantar erythrodysesthesia or other toxicity requiring dose modification?

Gastrointestinal Cancer Targets

Researchers from Johns Hopkins University report on a cascade of events that appears to correlate with early cancer recurrence and decreased overall survival.

The FDA has approved regorafenib (Stivarga) for the second-line treatment of hepatocellular carcinoma (HCC) for patients who have previously received sorafenib.

Researchers in Seattle are now reporting success with a biopolymer synthetic scaffold loaded with cancer-fighting T cells and a mix of nutrients to potentially combat solid tumors.

Researchers at the Johns Hopkins University Bloomberg School of Public Health say they have found several gene variants which may predispose individuals to develop gall bladder cancer.

We spoke with Dr. Luis Diaz about his recent presentation on immunotherapy in colorectal cancer at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.

In my practice, I am constantly being asked how to properly treat scalp involvement in relation to these skin toxicities.

New data are suggesting that deciphering the genomic diversity and evolution of tumors may provide a basis for identifying new targets and designing improved personalized medicine strategies.


Subscribe to Gastrointestinal Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.